Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022007966 - PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Publication Number WO/2022/007966
Publication Date 13.01.2022
International Application No. PCT/CN2021/105622
International Filing Date 09.07.2021
IPC
C07D 487/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 401/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 471/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/53 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
53having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/44 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
A61P 31/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
CPC
A61K 31/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
A61K 31/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
53having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 31/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
16for influenza or rhinoviruses
C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring-member bond
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • 四川海思科制药有限公司 SICHUAN HAISCO PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 李瑶 LI, Yao
  • 陈雷 CHEN, Lei
  • 石宗军 SHI, Zongjun
  • 张国彪 ZHANG, Guobiao
  • 王文晶 WANG, Wenjing
  • 叶飞 YE, Fei
  • 胡刚 HU, Gang
  • 贺天成 HE, Tiancheng
  • 王浩东 WANG, Haodong
  • 倪佳 NI, Jia
  • 张晨 ZHANG, Chen
  • 严庞科 YAN, Pangke
Agents
  • 北京坤瑞律师事务所 WU, FENG & ZHANG
Priority Data
202010658037.910.07.2020CN
202011121839.220.10.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF
(FR) INHIBITEUR DE PB2, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
(ZH) PB2抑制剂及其制备方法和用途
Abstract
(EN) The present invention relates to a compound of formula (I); a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt, a co-crystal or a prodrug thereof, or a pharmaceutical composition containing same; and the use thereof as a PB2 inhibitor in the preparation of a drug for treating related diseases. Each group in formula (I) is as defined in the description. Cy1-L1-Cy2-L2-Cy3 (I)
(FR) La présente invention concerne un composé de formule (I); un stéréoisomère, un tautomère, un oxyde d'azote, un solvate, un métabolite, un sel pharmaceutiquement acceptable, un co-cristal ou un promédicament de celui-ci, ou une composition pharmaceutique le contenant; et son utilisation en tant qu'inhibiteur de PB2 dans la préparation d'un médicament pour le traitement de maladies associées. Chaque groupe dans la formule (I) est tel que défini dans la description. Cy1-L1-Cy2-L2-Cy3 (I)
(ZH) 涉及一种式(I)的化合物,其立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐、共晶或前药,或含它们的药物组合物,及其作为PB2抑制剂在制备治疗相关疾病的药物中的用途,式(I)中各基团如说明书之定义。 Cy 1-L 1-Cy 2-L 2-Cy 3 (I)
Latest bibliographic data on file with the International Bureau